Evidence map›Paper›PMID 28928822›Full record

ArticleOncology letters2017

Long non-coding RNA Igf2as controls hepatocellular carcinoma progression through the ERK/MAPK signaling pathway.

Han Bao, Chun-Guang Guo, Peng-Cheng Qiu, Xin-Lei Zhang, Qi Dong, Yu-Kun Wang

RetractedOpen access · diamondAbstract readRetracted Publication
In one paragraph

Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Han BaoDepartment of Pharmacy Administration and Drug Information, School of Pharmacy, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China.
Chun-Guang GuoDepartment of Second Hepatobiliary Surgery, The First People's Hospital of Xianyang City, Shaanxi 712000, P.R. China.
Peng-Cheng QiuDepartment of Pharmacy Administration and Drug Information, School of Pharmacy, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China.
Xin-Lei ZhangDepartment of Pharmacy Administration and Drug Information, School of Pharmacy, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China.
Qi DongDepartment of Nano Fusion Technology, Pusan University, Miryang, Kyungnam 609-735, Republic of Korea.
Yu-Kun WangDepartment of Pharmacy Administration and Drug Information, School of Pharmacy, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China.
Air Force Medical University · CNKyungnam College of Information and Technology · KRXian Yang Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long non-coding RNAs (lncRNAs) serve an important role in numerous human diseases, including cancer. Abnormal expression of lncRNAs has been associated with a number of tumor types; however, the underlying mechanisms through which lncRNA functions have yet to be elucidated. The present study primarily focuses on insulin-like growth factor 2 antisense 1 (Igf2as), a lncRNA reported to be differentially expressed in hepatocellular carcinoma (HCC). Reverse transcription-quantitative polymerase chain reaction analysis was used to determine the level of Igf2as in HCC cells and tissues. Flow cytometry was used to determine the level of cell apoptosis following Igf2as suppression and western blot analysis was used to identify altered protein expression levels. The results demonstrated that Igf2as was upregulated in HCC cells and tissues, and that the inhibition of Igf2as using a targeted small interfering RNA (si-Igf2as), significantly decreased cell proliferation and increased apoptosis. Western blot analysis identified that the extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) signaling pathway was inhibited in cells transfected with si-Igf2as. In addition, cell migration was markedly reduced by the knockdown of Igf2as. These results suggest that lncRNA Igf2as may control hepatocellular progression primarily through the regulation of the ERK/MAPK signaling pathway.

Indexed as

cell proliferationextracellular signal-regulated kinases/mitogen-activated protein kinasehepatocellular carcinomaIgf2as

Identifiers

PMID28928822
PMCPMC5588175
OpenAlexW2622186501

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.